基本信息
views: 95
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr. Lencer is Professor and Longwood Chair in Pediatrics at Harvard Medical School, Director of the Harvard Digestive Diseases Center, and Division Chief of Pediatric Gastroenterology and Nutrition at Children’s Hospital Boston. He obtained his BA in Literature with honors Phi Beta Kappa from the University of Michigan, and his MD with honors form Boston University Medical School. His postdoctoral work in epithelia cell biology was with Dennis Brown, Alan Verkman, Dennis Ausiello, Marian Neutra and Jim Madara.
Dr. Lencer’s laboratory studies the cell and molecular biology of vesicular transport in polarized epithelial cells and regulation of ion transport in the intestine. These projects relate to how intestinal epithelial cells interact with the luminal and sub-epithelial microenvironment, and to the biology of bacterial pathogenesis and mucosal host defense. We have discovered how some enteric bacterial toxins breech the intestinal epithelial barrier and enter host epithelial cells to cause disease. These toxins hijack the cellular and molecular mechanisms of retrograde membrane transport to move from the luminal cell surface into the endoplasmic reticulum (ER) and then into the cytosol of affected cells, almost the total reverse of protein biosynthesis. In another project, the lab studies the cell and molecular biology of the MHC Class I-like IgG receptor FcRn. FcRn transports IgG across mucosal surfaces where it may function in immune surveillance and host defense. Both projects address fundamental mechanisms in membrane trafficking unique to polarized epithelial cells that line mucosal surfaces. In a third area of interest, the lab aims to understand the mechanisms and regulation of intestinal Cl- secretion, the initial ion transport event in secretory diarrhea.
His work in each of these areas has led to over 14 patent awards. We have a new patent application pending review, which is based on recent discoveries made on sphingolipid biology in the toxin project. The FcRn research program led to the founding of a Biotech company that was acquired by Biogen Idec and has two drugs with completed and strongly positive phase-3 clinical trials. One was recently FDA approved.
Research Interests
Papers共 329 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Bin Bao, Youyuan Wang, Pavl Boudreau,Xinyang Song, Meng Wu,Xi Chen, Izabel Patik,Ying Tang, Jodie Ouahed, Amit Ringel,Jared Barends, Chuan Wu,
Cellular and molecular gastroenterology and hepatologyno. 2 (2024): 101350-101350
Mariska S Simpson,Heidi De Luca, Sarah Cauthorn,Phi Luong,Namrata D Udeshi,Tanya Svinkina,Stefanie S Schmieder, Steven A Carr,Michael J Grey,Wayne I Lencer
The Journal of cell biologyno. 7 (2024)
Mariska Simpson,Heidi De Luca, Sarah Cauthorn,Phi Luong,Namrata Udeshi,Tanya Svinkina, Stefanie Schmeider,Steven Carr,Michael Grey,Wayne Lencer
bioRxiv (Cold Spring Harbor Laboratory)no. 12 (2023)
Cited0Views0Bibtex
0
0
STAR Protocolsno. 2 (2023): 102335-102335
Gastroenterologyno. 7 (2022): S997-S997
JOURNAL OF CLINICAL INVESTIGATIONno. 17 (2022): S592-S592
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn